In a filing, Insmed Inc revealed its Chief People Strategy Officer Schaeffer Orlov S Nicole unloaded Company’s shares for reported $5.82 million on Nov 12 ’25. In the deal valued at $194.00 per share,30,000 shares were sold. As a result of this transaction, Schaeffer Orlov S Nicole now holds 36,461 shares worth roughly $7.04 million.
Then, Flammer Martina M.D. sold 31,226 shares, generating $5,922,795 in total proceeds. Upon selling the shares at $189.68, the Chief Medical Officer now owns 83,111 shares.
Before that, ANDERSON ELIZABETH M bought 10,000 shares. Insmed Inc shares valued at $1,940,000 were divested by the Director at a price of $194.00 per share.
A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in mid October with a ‘”an Overweight”‘ rating. William Blair began covering INSM with “an Outperform” recommendation on August 20, 2025. Morgan Stanley revised its rating on August 13, 2025. It rated INSM as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of INSM
On Friday, Insmed Inc [NASDAQ:INSM] saw its stock jump 1.18% to $193.22. Over the last five days, the stock has gained 1.86%. Insmed Inc shares have risen nearly 175.48% since the year began. Nevertheless, the stocks have risen 179.87% over the past one year. While a 52-week high of $197.08 was reached on 11/14/25, a 52-week low of $60.40 was recorded on 04/09/25.
Levels Of Support And Resistance For INSM Stock
The 24-hour chart illustrates a support level at 188.03, which if violated will result in even more drops to 182.84. On the upside, there is a resistance level at 197.93. A further resistance level may holdings at 202.63.
How much short interest is there in Insmed Inc?
A steep rise in short interest was recorded in Insmed Inc stocks on 2025-10-31, dropping by -2.69 million shares to a total of 8.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 10.73 million shares. There was a decline of -33.54%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 13, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $105 price target.
